Granules India profit surges 60% on margin expansion

The Indian drugmaker's first-quarter results highlight improving profitability in the complex generics segment, adding to a wave of strong earnings from Indian financials.

By Handelsavisen Newsroom · Automated 2026-07-21 12:39 UTC · 1 min read

Granules India reported a nearly 60% increase in first-quarter profit, driven by expanding margins in its complex generics business.

The Hyderabad-based drugmaker also saw total revenue from operations climb 22% to 14.77 billion Indian rupees, supported by higher sales of finished medicines.

Earlier this week, Indian Bank shares jumped nearly 10% after reporting robust profit growth, while RBL Bank also posted a rise in first-quarter profit driven by loan book expansion.

The results underscore a positive trend for Indian pharmaceutical companies, which are benefiting from improved pricing power and operational efficiency.

Granules India’s performance comes as investors look for signs of sustained growth in the sector, particularly in the complex generics niche where barriers to entry are higher.

This earnings beat adds to a broader wave of strong first-quarter results from Indian companies.

Earlier this week, Indian Bank shares jumped nearly 10% after reporting robust profit growth, while RBL Bank also posted a rise in first-quarter profit driven by loan book expansion.